Biotron Limited (AU:BIT) has released an update.
Biotron Limited announced that their Phase 2 clinical trial of BIT225, a lead antiviral drug for treating COVID-19, met its primary safety endpoint but did not achieve its primary efficacy endpoint in reducing nasal viral load. Despite this, a post hoc analysis showed a significant reduction in viral loads in the BIT225 dosage groups compared to placebo, particularly in participants with higher initial viral loads. The company remains committed to its platform of viroporin antagonists, with optimistic views on its potential against significant viral infections.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
